Company Overview
Pluri Inc. is a biotechnology firm dedicated to the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies intended for various industries. The company specifically focuses on creating placenta-based cell therapy product candidates aimed at treating conditions such as inflammatory disorders, muscle injuries, and other medical needs. Operating within the broader healthcare sector and the specialized biotechnology industry, Pluri Inc. targets markets where advanced cellular solutions can address unmet medical needs. The company operates with a market capitalization of $32.56M and generated annual revenue of $1.34M over the trailing twelve months, supported by a workforce of 127 employees. These financial figures indicate that Pluri Inc. maintains a relatively small market presence, characteristic of early-stage or specialized biotechnology entities that are still scaling their product pipelines rather than generating massive commercial profits. The disparity between its modest revenue stream and its established employee base suggests an organization heavily invested in human capital and research infrastructure while navigating the high costs typical of the biotechnology sector.
Financial Health
Pluri Inc. reported a revenue of $1.34M for the trailing twelve months, yet it posted a net income of -$26,138,000 and an EBITDA of -$24,435,000, revealing a significant gap between top-line sales and bottom-line profitability. This substantial divergence highlights a cost structure dominated by research and development expenses, operational overhead, and potentially clinical trial costs that far exceed current revenue generation. The company generated free cash flow of -$14,348,750, indicating that its current operations consume more cash than they produce, which limits immediate financial flexibility without external capital injections. In terms of profitability margins, the firm displays a gross margin of 40.6%, suggesting that its core production costs are managed reasonably well relative to sales, but the operating margin stands at -3285.9% and the profit margin at 0.0%, reflecting severe inefficiencies or high non-operating costs that erode value before reaching the bottom line. Regarding liquidity and leverage, the company holds $12.48M in cash against $34.94M in debt, creating a situation where liabilities significantly outweigh liquid assets, and the debt-to-equity ratio is listed as N/A due to the negative equity position implied by the financial data. The current ratio is 0.43, which indicates that the company possesses less than half of the current assets required to cover its current liabilities, signaling potential short-term liquidity constraints. Furthermore, the return on equity is N/A and the return on assets is -50.6%, metrics that reveal management is currently generating negative returns on the capital invested in the company.
Valuation Assessment
The valuation metrics for Pluri Inc. include a trailing P/E ratio of N/A and a forward P/E of -1.71, implying that the market does not yet anticipate positive earnings normalization in the near term. The price-to-book ratio is recorded at -2.21, a negative figure that indicates the market values the company's equity below its book value, often seen in capital-intensive biotechnology firms with significant intangible assets or liabilities. Alternative valuation measures such as the price-to-sales ratio of 24.32 and an EV/EBITDA of -2.47 suggest that the stock is priced heavily on future growth expectations rather than current earnings power or asset backing. The stock's price has fluctuated between a 52-week high of $7.13 and a 52-week low of $2.82, and without a specific current price provided in the source data, the valuation relative to this range cannot be precisely calculated, though the wide spread indicates high volatility. The beta value is 0.73, meaning the stock's price volatility is lower than the broader market average, suggesting that despite its high valuation multiples, the stock may not move as sharply as the overall market index in either direction.
Growth & Income
Pluri Inc. achieved a revenue growth rate of 7.0% year-over-year, while earnings growth is listed as N/A due to the company's continued losses; consequently, earnings are not growing faster than revenue because there is no positive earnings base to measure against. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any potential earnings are theoretically available for reinvestment or are entirely absorbed by operational deficits. As a non-dividend payer, Pluri Inc. must reinvest its limited resources and future earnings into growth initiatives, such as advancing its placenta-based cell therapy candidates and expanding its research portfolio, rather than returning cash to shareholders. The overall growth and income profile for Pluri Inc. is defined by modest top-line expansion in a high-cost industry, coupled with a complete lack of current income generation and a reliance on external capital to sustain operations and fund future product development.